Next > ARTICLE LINKS: TRASTUZUMAB AND VINORELBINE AS FIRST-LINE THERAPY FOR HER2-OVEREXPRESSING METASTATIC BREAST CANCER: MULTICENTER PHASE II AND PHARMACOKINETIC STUDY IN JAPAN.CLINICAL REPORTS Anti-Cancer Drugs.August 2008.Tokudome, Nahomi a; Ito, Yoshinori a; Hatake, Kiyohiko a; Toi, Masakazu b; Sano, Muneaki c; Iwata, Hiroji d; Sato, Yasuyuki e; Saeki, Toshiaki f; Aogi, Kenjiro f; Takashima, Shigemitsu f _ ABSTRACT: Tolerability and response rate to weeklybination chemotherapy with trastuzumab and vinorelbine in Japanese women with HER2-overexpressing breast cancer not previously receiving either therapy were assessed.Was evaluated every 4 weeks and adverse events were graded.Total of 23 patients from six participating centers in Japan were enrolled.Dose intensity of vinorelbine was 16.Response rate was 73% plete response+partial response);plete response=9%, partial response=64%, and progressive disease=5%.To progression was 361 days, with 75.Liver metastases and 60% of lung metastases responding to this treatment.Adverse events were leukocytopenia and neutropenia (96%); however, hematologic toxicity associated with vinorelbine was manageable by adjusting the dose.Pharmacokinetic differences for vinorelbine were found between single administration andbination with trastuzumab.Therapy produced high response rates and good tolerability, indicating a promising role in first-line chemotherapy for HER2-overexpressing metastatic breast cancer in Japan.Williams & Wilkins, Inc.Copyright 2008, Lippincott Williams & Wilkins.Rights reserved.By Lippincott Williams & Wilkins.Read more Azathioprine/methylprednisolone/tacrolimus: cns disorders associated with cryptococcal infection in a liver transplant recipient: case report
Get more Valsartan may be more effective for preventing cardiovascular (cv) and renal events in hypertensive patients than extended-release (er) metoprolol
